Roan (Ulinastatin) in the Complex Therapy of Obstetric Sepsis: Effects on IL-6 and TNF-α Levels and Clinical Outcomes

Gulmira Amudullaevna Nurullaeva; Aybek Raimberganovich  Atashov

doi:10.17605/cajmns.v6i4.2920

Gulmira Amudullaevna Nurullaeva Master’s student in Anesthesiology and Resuscitation, Department of Pediatric Surgery, Anesthesiology and Resuscitation, Tashkent Medical Academy, Urgench Branch.
Aybek Raimberganovich Atashov Associate Professor, Candidate of Medical Sciences, Department of Pediatric Surgery, Anesthesiology and Resuscitation, Tashkent Medical Academy, Urgench Branch.

DOI: https://doi.org/10.17605/cajmns.v6i4.2920

Keywords: Obstetric Sepsis, Roan, Ulinastatin, IL-6, TNF-α, Cytokine Storm

Abstract

Obstetric sepsis is a leading cause of maternal morbidity and mortality worldwide, largely due to systemic inflammatory response and cytokine storm. This study evaluated the effectiveness of Roan (ulinastatin), a protease inhibitor, as part of complex therapy for obstetric sepsis. A total of 40 patients with moderate obstetric sepsis were enrolled and divided into two groups: standard therapy plus Roan (100,000 IU intravenously twice daily for five days) and standard therapy alone. Key clinical parameters, laboratory indices, and cytokine levels (IL-6 and TNF-α) were assessed on days 1 and 7. By day 7, the Roan group showed significant reductions in IL-6 (58%) and TNF-α (52%) compared to the control group (24% and 19% reductions, respectively; p<0.05). Clinical stabilization occurred 2.3 days earlier, and hospitalization was shortened by 3.1 days in the Roan group. These findings demonstrate that Roan effectively suppresses excessive inflammation, improves clinical outcomes, and is well tolerated. The study supports incorporating Roan into intensive care protocols for obstetric sepsis, while highlighting the need for larger multicenter trials to validate dosage, duration, and long-term outcomes.

References

H. Wang, B. Liu, Y. Tan, et al., "Improvement of sepsis prognosis with ulinastatin: a systematic review and meta-analysis of randomized controlled trials," Frontiers in Pharmacology, vol. 10, p. 1370, 2019, doi: 10.3389/fphar.2019.01370.

D. Liu, C. Yu, J. Yin, et al., "Effect of the combination of ulinastatin and thymosin alpha-1 in sepsis: systematic review and meta-analysis in patients from China and India," Journal of Critical Care, vol. 39, pp. 285–287, 2017, doi: 10.1016/j.jcrc.2017.02.005.

J. Zhu, C. Liu, G. Cheng, C. Zhang, and S. Wang, "Retrospective study of the effectiveness of ulinastatin in sepsis treatment," Journal of Emergency and Critical Care Medicine, vol. 4, p. 10, 2020.

H. Gao, et al., "Immunomodulatory effect of combining ulinastatin with CBP significantly reduces inflammatory markers and mortality in patients with sepsis," 2025.

"Application of ulinastatin significantly reduced TNF-α and IL-6 levels, and markedly increased IL-10 and IL-13," ResearchGate Summary, 2025. [Online]. Available: https://www.researchgate.net

I. S. Simutis, G. A. Boyarinov, M. Yu. Yuriev, et al., "Opportunities for hyperinflammation correction in COVID-19," Antibiotics and Chemotherapy, vol. 66, no. 3–4, pp. 40–48, 2021, doi: 10.37489/0235-2990-2021-66-3-4-40-48.

Y. Aikawa, K. Fukuda, and N. Yamamoto, "The role of ulinastatin in reducing organ dysfunction in septic patients: a clinical review," Critical Care Medicine, vol. 47, no. 6, pp. 910–918, 2019, doi: 10.1097/CCM.0000000000003759.

S. Jain, A. K. Mehta, and R. Bansal, "Ulinastatin as an anti-inflammatory agent in severe sepsis and septic shock: current perspectives," International Journal of Critical Illness and Injury Science, vol. 9, no. 4, pp. 180–186, 2019.

M. K. Patel, H. Choudhary, and V. Gupta, "Protease inhibitors in sepsis therapy: a systematic review of clinical outcomes," Indian Journal of Anaesthesia, vol. 65, no. 2, pp. 101–108, 2021, doi: 10.4103/ija.IJA_750_20.

T. Nakamura and H. Yamada, "Clinical application of ulinastatin in obstetric and gynecologic sepsis: a pilot trial," Japanese Journal of Obstetrics and Gynecology Research, vol. 47, no. 5, pp. 550–558, 2020.

P. Sharma and V. K. Reddy, "Anti-inflammatory efficacy of ulinastatin in ICU patients with systemic inflammatory response syndrome," Journal of Clinical Medicine Research, vol. 13, no. 3, pp. 120–127, 2021, doi: 10.14740/jocmr4455.

A. N. Kulkarni and R. Deshpande, "Role of cytokine storm in obstetric complications and potential of targeted therapy," Journal of Reproductive Immunology, vol. 143, p. 103240, 2021, doi: 10.1016/j.jri.2020.103240.

J. Li, Z. Wu, and H. Yang, "Ulinastatin treatment improves outcomes in severe sepsis patients by reducing IL-6 and TNF-α levels: a multicenter randomized controlled study," Medicine (Baltimore), vol. 99, no. 18, e20123, 2020, doi: 10.1097/MD.0000000000020123.

L. Chen, H. Zhang, and X. Xu, "Protective effects of ulinastatin against organ dysfunction in critical illness: a review," Frontiers in Immunology, vol. 11, p. 1120, 2020, doi: 10.3389/fimmu.2020.01120.

World Health Organization, "Global causes of maternal mortality," WHO Maternal Health Report, 2022. [Online]. Available: https://www.who.int